Effective elimination of cancer stem cells by a novel drug combination strategy

Shuqiang Yuan, Feng Wang, Gang Chen, Hui Zhang, Li Feng, Lei Wang, Howard Colman, Michael J. Keating, Xiaonan Li, Rui Hua Xu, Jianping Wang, Peng Huang*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

63 Scopus citations


Development of effective therapeutic strategies to eliminate cancer stem cells, which play a major role in drug resistance and disease recurrence, is critical to improve cancer treatment outcomes. Our study showed that glioblastoma stem cells (GSCs) exhibited low mitochondrial respiration and high glycolytic activity. These GSCs were highly resistant to standard drugs such as carmustine and temozolomide (TMZ), but showed high sensitivity to a glycolytic inhibitor 3-bromo-2-oxopropionate-1-propyl ester (3-BrOP), especially under hypoxic conditions. We further showed that combination of 3-BrOP with carmustine but not with TMZ achieved a striking synergistic effect and effectively killed GSCs through a rapid depletion of cellular ATP and inhibition of carmustine-induced DNA repair. This drug combination significantly impaired the sphere-forming ability of GSCs in vitro and tumor formation in vivo, leading to increase in the overall survival of mice bearing orthotopic inoculation of GSCs. Further mechanistic study showed that 3-BrOP and carmustine inhibited glyceraldehyde-3-phosphate dehydrogenase and caused a severe energy crisis in GSCs. Our study suggests that GSCs are highly glycolytic and that certain drug combination strategies can be used to effectively overcome their drug resistance based on their metabolic properties.

Original languageEnglish (US)
Pages (from-to)23-34
Number of pages12
JournalStem Cells
Issue number1
StatePublished - Jan 2013


  • Chemotherapy
  • Drug target
  • Glioma
  • Hypoxia
  • Toxicity

ASJC Scopus subject areas

  • Molecular Medicine
  • Developmental Biology
  • Cell Biology


Dive into the research topics of 'Effective elimination of cancer stem cells by a novel drug combination strategy'. Together they form a unique fingerprint.

Cite this